KRAS Oncogene Connect
  • Saved

made a Post

5yr
Post-Conference Recap of the 2021 ASCO Virtual Meeting

Click on the icon above to preview and download our post-conference coverage of the 2021 ASCO Virtual Meeting


  • Saved

made a Post

5yr
Post-Conference Recap of the 2021 ASCO Virtual Meeting

Click on the icon above to preview and download our post-conference coverage of the 2021 ASCO Virtual Meeting


  • Saved

5yr

Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors - PubMed

Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34064352/

Activating mutations in RAS family proteins are found in ~25% of all human cancers. Different solid tumors are correlated with mutations in certain isoforms of RAS, with Kirsten RAS (KRAS)...

  • 5yr
      Key Points • In the current review, authors examined current trends in targeting KRAS mutations, including the current challenges and future directions of KRAS inhibitors. • They acknowledged that current agents targeting Show More
  • Saved

5yr

KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing - PubMed

KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/33618059/

Mutation in the gene that encodes Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common oncogenic driver in advanced non-small cell lung cancer, occurring in approximately 30% of...

  • Saved

5yr

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From the In Vitro Experiments - PubMed

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From the In Vitro Experiments - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/33971321/

We identified many secondary KRAS mutations causing resistance to sotorasib, adagrasib, or both, in vitro. The differential activities of these two inhibitors depending on the secondary mutations suggest sequential use...